Anti-Proliferative Effect of Rosa Agrestis on Endometrium Cancer Cells In Vitro

Year 2015, Volume: 1 Issue: 1, 17 - 23, 01.06.2015

Mine Ergüven Sükran Kültür Nurten Özsoy

Abstract

Endometrial cancer is the most common gynaecological malignant disease. Despite of some arguments about the preference of herbal medicine to pharmaceutical drugs, because of their minimal side effects herbal medicine is proven to be effective as a single application and/or an adjuvant therapy. Rosa agretis Savi R. agretis Savi which belongs to Rosaceae family has been used traditionally to treat allergy, antiatopic dermatitis, and some inflammatory diseases, is commonly studied. Anti-oxidant activity is also reported. The present study was undertaken to investigate the in vitro anticancer activity of R. agrestis parts leaves, flowers at endometrium cancer. Extracts in a concentration of 1 µg/ml to 200 µg/ml from leaves and flowers were tested on human endometrium cell line named Ischikawa for 72 h. Cell proliferation total cell number and apoptotic index flow cytometry were evaluated for 72 h. All the results were statistically analyzed using the independent Student’s t-test. All extracts decreased cell number and increased apoptotic index with dead cells in concentration and time dependent manner p

Keywords

Rosa agrestis Savi, endometrium cancer, anticancer activity

References

• SGO Clinical Practice Endometrial Cancer Working Group, Burke WM, Orr J, Leitao M, Salom E, Gehrig P, Olawaiye AB, Brewer M, Boruta D, Herzog TJ, Shahin FA; Society of Gynecologic Oncology Clinical Practice Committee, “Endometrial cancer: a review and current management strategies: part II”, Gynecol Oncol., vol 134, pp. 393-402, 2014.
• SGO Clinical Practice Endometrial Cancer Working Group, Burke WM, Orr J, Leitao M, Salom E, Gehrig P, Olawaiye AB, Brewer M, Boruta D, Villella J, Herzog T, Abu Shahin F; Society of Gynecologic Oncology Clinical Practice Committee, “Endometrial cancer: a review and current management strategies: part I.”, Gynecol Oncol., vol 134, pp. 385-92, 2014. Erratum in
• Gynecol Oncol. vol 135, pp 625, Villella, Jeanine [corrected to Villella, Jeannine]. Liu Y, Broaddus RR, Zhang W, “Identifying aggressive forms of endometrioid-type endometrial cancer: new insights into molecular subtyping.”, Expert Rev Anticancer Ther.,vol 15, pp. 1-3, 2015.
• Murali R, Soslow RA, Weigelt B, “Classification of endometrial carcinoma: more than two types.”, Lancet Oncol., vol 15, pp. e268-78, 2014
• Rezaei A, Farzadfard A, Amirahmadi A, Alemi M, Khademi M, “Docsubty: REVDiabetes Mellitus and its management with medicinal plants: A perspective based on Iranian Research.”, J Ethnopharmacol. vol 14, pp. JEPD1403686, 2015.
• Kim W, Lee WB, Lee JW, Min BI, Baek SK, Lee HS, Cho SH, “Traditional herbal medicine as adjunctive therapy for breast cancer: A systematic review.”, Complement Ther Med., vol 23, pp 26-32. 2015.
• Bitis L, Kultur S, Melikoglu G, Ozsoy N, Can A. “Flavonoids and antioxidant activity of Rosa agrestis leaves”, Nat Prod Res., vol 24, pp. 580-9, 2010.
• Serbetçi T, Demirci B, Güzel CB, Kültür S, Ergüven M, Başer KH, “Essential oil composition, antimicrobial and cytotoxic activities of two endemic Stachys cretica subspecies (Lamiaceae) from Turkey.”, Nat Prod Commun. vol 5, pp. 1369-74, 2010.
• Bilir A, Erguven M, Ermis E, Sencan M, Yazihan N, “ Combination of imatinib mesylate with lithium chloride and medroxyprogesterone acetate is highly active in Ishikawa endometrial carcinoma in vitro.” J Gynecol Oncol., vol 22, pp. 225-32, 2011.
• Ma Z, Piao T, Wang Y, Liu J, “Astragalin inhibits IL- β-induced inflammatory mediators production in human osteoarthritis chondrocyte by inhibiting NF-κB and MAPK activation.”, Int Immunopharmacol., vol 25, pp 83-7, 2015.
• Li F, Wang W, Cao Y, Liang D, Zhang W, Zhang Z, Jiang H, Guo M, Zhang N, “Inhibitory effects of astragalin on lipopolysaccharide- induced inflammatory response in mouse mammary epithelial cells” J Surg Res., vol 192, pp. 573-81, 2014.
• Li F, Liang D, Yang Z, Wang T, Wang W, Song X, Guo M, Zhou E, Li D, Cao Y, Zhang N., “ Astragalin suppresses inflammatory responses via down-regulation of NF-κB signaling pathway in lipopolysaccharide-induced mastitis in a murine model.” , Int Immunopharmacol. vol 17, pp. 478- 2013.
• Kim MS, Kim SH., “Inhibitory effect of astragalin on expression of lipopolysaccharide-induced inflammatory mediators through NF- κB in macrophages.”, Arch Pharm Res., vol 34, pp. 2101-7, 2011.